World Journal of Surgery

, Volume 33, Issue 2, pp 272–277 | Cite as

Perioperative Changes of Serum p53 Antibody Titer is a Predictor for Survival in Patients with Esophageal Squamous Cell Carcinoma

  • Hideaki ShimadaEmail author
  • Tooru Shiratori
  • Akihiko Takeda
  • Kazuyuki Matsushita
  • Shinichi Okazumi
  • Yasunori Akutsu
  • Hisahiro Matsubara
  • Fumio Nomura
  • Takenori Ochiai



Although the presence of serum p53 antibody (s-p53-Abs) before treatment has been shown to correlate with poor prognosis and lymph node metastasis in esophageal cancer, there has been little information about postoperative s-p53-Abs titer and perioperative changes of s-p53-Abs titers in patients with esophageal carcinoma.


A highly specific enzyme-linked immunosorbent assay was used to analyze s-p53-Abs in 110 patients with esophageal squamous cell carcinoma before and 1 month after surgery. The cutoff level of 1.3 U/ml was used to indicate seropositive patients. Impact of postoperative s-p53-Abs titer and perioperative changes of s-p53-Abs on survival was evaluated.


Forty (36%) of 110 patients were positive for s-p53-Abs before surgery and 35 patients (32%) were positive after surgery. s-p53-Abs titer generally decreased after surgery. Among sero-positive patients, the patients who remained sero-positive after surgery (n = 28) had a worse prognosis than patients who showed sero-conversion (P = 0.02). Among sero-positive patients, the nondecreased titer group showed significantly unfavorable survival (P < 0.01). Multivariate analysis revealed that postoperative s-p53-Abs was an independent risk factor for worse overall survival (adjusted hazard ratio = 3.05; 95% confidence interval = 1.11–8.33; P = 0.03).


Perioperative monitoring of s-p53-Abs titers was useful to identify patients with esophageal cancer with a high risk for tumor recurrence and a poor prognosis. Continuous sero-positive patients and/or nondecreased titer group, even after surgery, showed significantly unfavorable survival.


Esophageal Cancer Esophageal Squamous Cell Carcinoma Serum Titer Seropositive Patient Titer Group 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Shimada H, Takeda A, Arima M et al (2000) Serum p53 antibody is a useful tumor marker in superficial esophageal squamous cell carcinoma. Cancer 89:1677–1683PubMedCrossRefGoogle Scholar
  2. 2.
    Soussi T, Legros Y, Lubin R, Ory K, Schlichtholz B (1994) Multi factorial analysis of p53 alteration in human cancer: a review. Int J Cancer 57:1–9PubMedCrossRefGoogle Scholar
  3. 3.
    Hollstein MC, Metcalf RA, Welsh JA et al (1990) Frequent mutation of the p53 gene in human esophageal cancer. Proc Natl Acad Sci 87:9958–9961PubMedCrossRefGoogle Scholar
  4. 4.
    Coggi G, Bosari S, Roncalli M et al (1997) p53 protein accumulation and p53 gene mutation in esophageal carcinoma. Cancer 79:425–432PubMedCrossRefGoogle Scholar
  5. 5.
    Sarbia M, Porschen R, Borchard F et al (1994) p53 protein expression and prognosis in squamous cell carcinoma of the esophagus. Cancer 74:2218–2223PubMedCrossRefGoogle Scholar
  6. 6.
    von Brevern MC, Hollstein MC, Cawley HM et al (1996) Circulating anti-p53 antibodies in esophageal cancer patients are found predominantly in individuals with p53 core domain mutations in their tumors. Cancer Res 56:4917–4921Google Scholar
  7. 7.
    Collet B, Raoul JL, Berre NL et al (1997) Serum anti-p53 antibodies in patients with squamous cell carcinoma of the esophagus: comparison with p53 alterations and lymph node invasion. Int J Oncol 11:617–621Google Scholar
  8. 8.
    Shimada H, Nabeya Y, Okazumi S et al (2002) Prognostic significance of serum p53 antibody in patients with esophageal squamous cell carcinoma. Surgery 132:41–47PubMedCrossRefGoogle Scholar
  9. 9.
    Sobti RC, Parashar K (1998) A study on p53 protein and anti-p53 antibodies in the sera of patients with esophageal cancer. Mutat Res 422:271–277PubMedGoogle Scholar
  10. 10.
    Ralhan R, Arora S, Chattopadhyay TK et al (2000) Circulating p53 antibodies, p53 gene mutational profile and product accumulation in esophageal squamous cell carcinoma in India. Int J Cancer 85:791–795PubMedCrossRefGoogle Scholar
  11. 11.
    Takahashi K, Miyashita M, Nomura T et al (2007) Serum p53 antibody as a predictor of early recurrence in patients with postoperative esophageal squamous cell carcinoma. Dis Esophagus 20:117–122PubMedCrossRefGoogle Scholar
  12. 12.
    Takeda A, Shimada H, Nakajima K et al (2001) Monitoring of p53 autoantibodies after resection of colorectal cancer: relationship to operative curability. Eur J Surg 167:50–53PubMedCrossRefGoogle Scholar
  13. 13.
    Sobin LH, Wittekind CH (eds) (2002) UICC International Union Against Cancer TNM classification of malignant tumors, 6th edn edn. Wiley, New YorkGoogle Scholar
  14. 14.
    Shimada H, Kitabayashi H, Nabeya Y et al (2003) Treatment response and prognosis of patients after recurrence of esophageal cancer. Surgery 133:24–31PubMedCrossRefGoogle Scholar
  15. 15.
    Shimada H, Ochiai T, Nomura F, Japan p53 Antibody Research Group (2003) Titration of serum p53 antibodies in 1, 085 patients with various types of malignant tumors: a multiinstitutional analysis by the Japan p53 Antibody Research Group. Cancer 97:682–689PubMedCrossRefGoogle Scholar
  16. 16.
    Zalcman G, Schlichtholz B, Tredaniel J et al (1998) Monitoring of p53 autoantibodies in lung cancer during therapy: relationship to response to treatment. Clin Cancer Res 4:1359–1366PubMedGoogle Scholar
  17. 17.
    Hammel P, Boissier B, Chaumette MT et al (1997) Detection and monitoring of serum p53 antibodies in patients with colorectal cancer. Gut 40:356–361PubMedGoogle Scholar

Copyright information

© Société Internationale de Chirurgie 2008

Authors and Affiliations

  • Hideaki Shimada
    • 1
    Email author
  • Tooru Shiratori
    • 2
  • Akihiko Takeda
    • 3
  • Kazuyuki Matsushita
    • 4
  • Shinichi Okazumi
    • 5
  • Yasunori Akutsu
    • 2
  • Hisahiro Matsubara
    • 2
  • Fumio Nomura
    • 4
  • Takenori Ochiai
    • 6
  1. 1.Department of Gastroenterological SurgeryChiba Cancer CenterChibaJapan
  2. 2.Frontier SurgeryChiba University Graduate School of MedicineChibaJapan
  3. 3.Department of Digestive SurgeryChemotherapy Research Institute Hospital International University of Health and WelfareIchikawaJapan
  4. 4.Department of Molecular DiagnosisChiba University Graduate School of MedicineChibaJapan
  5. 5.Department of SurgeryToho Sakura Medical CenterChibaJapan
  6. 6.Gastroenterological CenterSan-Ai Memorial HospitalChibaJapan

Personalised recommendations